Evotec to Collaborate With Fraunhofer in Joint Drug Discovery Programmes
July 08 2014 - 12:40AM
Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN:DE0005664809) announced
today an exclusive strategic collaboration with the Fraunhofer
Institute for Molecular Biology and Applied Ecology IME in several
disease areas through the combination of the relevant platforms of
both organisations for internal and external drug discovery
projects.
This alliance expands Evotec's already powerful drug discovery
platform with access to a broad range of complementary and highly
innovative platforms and capabilities to progress own innovate
projects and provides additional capabilities for customers and
partners of Evotec and IME, respectively. The deal follows the
joint decision of Evotec, Fraunhofer-Gesellschaft and the City of
Hamburg to integrate the European ScreeningPort GmbH into the IME
thereby forming the first Fraunhofer life science institution in
the City of Hamburg.
Dr. Werner Lanthaler, Chief Executive Officer of Evotec,
commented: "We are looking forward to partner with
Fraunhofer IME and are excited about the potential of this
alliance. The IME has an impressive track record for product
development and provides an ideal basis for collaborating with one
of the strongest science organisations in Germany and beyond. This
adds another footprint in Europe of our EVT Innovate programmes as
we have with US based academic institutions."
Prof. Dr. Rainer Fischer, Senior Executive Director at
the Fraunhofer IME stated: "This
collaboration constitutes a win-win situation through the
project-specific combination of first-in-class capabilities. In
particular, Evotec's medicinal chemistry and expertise will add
value to our own, our joint and our partner's programmes. We look
forward to collaborate with an experienced player in the life
science industry on several layers now and in the future."
ABOUT FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND
APPLIED ECOLOGY IME
The Fraunhofer Institute for Molecular Biology and Applied
Ecology IME conducts research in the field of applied life sciences
from a molecular level to entire ecosystems. Our interdisciplinary
organization features laboratories with the state of the art
infrastructure, including GMP production facilities and complex
facilities for environmental simulations, allowing a wide spectrum
of research and development services in the divisions of Molecular
Biology and Applied Ecology.
The Molecular Biology Division focuses on complex research and
projects in the business fields Drugs and Biopharmaceuticals,
Bioproduction and Industrial Biotechnology and Agroscience for Food
and Feed. The formation of the IME-SP is fully aligned with the
Fraunhofer IME mission to take innovative products closer towards
the market, to develop enabling technologies and provide scientific
services to partners from academic institutions and industry.
The Fraunhofer IME has approximately 600 employees working at
its laboratories in Aachen, Schmallenberg, Münster, Gießen and
Frankfurt as well as subsidiary research centers in the USA and in
Chile. The IME enjoys close ties with the Institute of Molecular
Biotechnology at RWTH Aachen University, the Department of
Biotechnology of Plants at the University Münster, the Department
of Applied Entomology at the University Gießen and the Institute
for Clinical Pharmacology at the Goethe University Frankfurt.
ABOUT EUROPEAN SCREENINGPORT GMBH
European ScreeningPort is located in Hamburg and was founded in
2008 as a public private partnership. Founding shareholders include
the Free and Hanseatic City of Hamburg and Evotec AG. The mission
of the European ScreeningPort ("ESP") was to bridge the gap between
basic academic research and the life sciences industry in the field
of drug discovery and development. With state-of-the-art
infrastructure at the VolksparkLabs in Hamburg, established
processes and innovative technologies, ESP was able to position
itself as a world-leading contract research organization for
small-molecule screening, particularly for targets identified by
academic partners. ESP was successful in the competitive
acquisition of public joint research projects (BMBF, EU, IMI) and
has already acquired full project capacity for several years to
come. Focusing on applied research, ESP has developed a strong
network of academic as well as pharmaceutical industry
partners.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership
company focused on rapidly progressing innovative product
approaches with leading pharmaceutical and biotechnology companies.
We operate worldwide providing the highest quality stand-alone and
integrated drug discovery solutions, covering all activities from
target-to-clinic. The Company has established a unique position by
assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and
expertise in key therapeutic areas including neuroscience, pain,
metabolic diseases as well as oncology and inflammation. Evotec has
long-term discovery alliances with partners including Bayer,
Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals,
MedImmune/AstraZeneca, Roche and UCB. In addition, the Company has
existing development partnerships and product candidates both in
clinical and pre-clinical development. These include partnerships
with Boehringer Ingelheim, MedImmune and Hyperion Therapeutics in
the field of diabetes, with Janssen Pharmaceuticals in the field of
depression and with Roche in the field of Alzheimer's disease. For
additional information please go to www.evotec.com.
FORWARD LOOKING STATEMENTS — Information set
forth in this press release contains forward-looking statements,
which involve a number of risks and uncertainties. The
forward-looking statements contained herein represent the judgement
of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to
a variety of risks and uncertainties, many of which are beyond our
control, and which could cause actual results to differ materially
from those contemplated in these forward-looking statements. We
expressly disclaim any obligation or undertaking to release
publicly any updates or revisions to any such statements to reflect
any change in our expectations or any change in events, conditions
or circumstances on which any such statement is based.
CONTACT: For further information, please contact
Gabriele Hansen
VP, Corporate Communications & Investor Relations
+49.(0)40.560 81-255
+49.(0)40.560 81-333 Fax
gabriele.hansen@evotec.com
Evotec AG
Manfred Eigen Campus
Essener Bogen 7
22419 Hamburg (Germany)
Eaton Vance Tax Advantag... (NYSE:EVT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Eaton Vance Tax Advantag... (NYSE:EVT)
Historical Stock Chart
From Jul 2023 to Jul 2024